Markets

Sanofi Opts into Alnylam's ALN-AT3 Hemophilia Program

An image of a smartphone with a spreadsheet on the display
Credit: Shutterstock photo

Alnylam Pharmaceuticals, Inc.ALNY announced that Sanofi's SNY subsidiary, Genzyme, has elected to opt into its ALN-AT3 hemophilia program. ALN-AT3 is currently being evaluated in a phase I study for the treatment of hemophilia and other rare bleeding disorders.

We remind investors that Alnylam has a collaboration agreement with Genzyme, for the development and commercialization of RNAi therapeutics. Under the terms of the agreement, while Alnylam retains product rights in North America and Western Europe, Genzyme obtained the right to access certain programs in Alnylam's current and future Genetic Medicines pipeline in the rest of the world (ROW) through 2019-end. In addition, both companies hold certain broader co-development/co-commercialization rights and global rights on certain products.

As per terms of the agreement, Alnylam is entitled to receive milestones of up to $75 million per product and up to $200 million per product for regional and co-development/co-promotion programs and in the case of global Genzyme programs, respectively. In addition, Alnylam is eligible to receive tiered double-digit royalties up to 20% on net sales on all products commercialized by Genzyme in its territories. However, profits will be equally shared by the companies when Genzyme co-develops/co-promote products in the Alnylam territory.

We note that, Genzyme still retains its future opt-in right to co-develop and co-promote the candidate with Alnylam in North America and Western Europe.

A pivotal phase III study is expected to be initiated in mid-2016.

Meanwhile, Alnylam continues to progress on the other two candidates - patisiran and revusiran - under Genzyme's alliance. Currently, the company is evaluating patisiran (in phase II open-label extension (OLE) study and phase III APOLLO study) for the treatment of transthyretin-mediated amyloidosis (ATTR amyloidosis) with familial amyloidotic polyneuropathy (FAP) and revusiran (in phase II OLE study and phase III ENDEAVOUR study) for the treatment of ATTR patients with familial amyloidotic cardiomyopathy (FAC).

Alnylam carries a Zacks Rank #3 (Hold). A couple of better-ranked stocks in the health care sector are Nexvet Biopharma Public Limited Company NVET and Regeneron Pharmaceuticals, Inc. REGN , each sporting a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

REGENERON PHARM (REGN): Free Stock Analysis Report

SANOFI-AVENTIS (SNY): Free Stock Analysis Report

ALNYLAM PHARMA (ALNY): Free Stock Analysis Report

NEXVET BIOPHARM (NVET): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

REGN ALNY SNY

Other Topics

Stocks

Latest Markets Videos

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More